ANDA 206670, held by Eugia Pharma. Vecuronium Bromide.
As of Nov 16, 2026, ANDA 206670 (Vecuronium Bromide), held by Eugia Pharma, was first approved by FDA on Dec 20, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Vecuronium bromide for injection is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2018 | Original application | Approved | None posted |
| Vecuronium Bromide10MG/VIAL · injectable;injection | Vecuronium Bromide | Rx |
| Vecuronium Bromide20MG/VIAL · injectable;injection | Vecuronium Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters